Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesPresentation and Progression of Benign Prostatic Hyperplasia: A Singapore Experience Profiling Ethnic Differences in a Multiracial Study Cohort
Annals, Academy of Medicine, Singapore, 06/12/09
Loh AHP et al. - Inter-ethnic differences in symptom perception and quantitative assessment of BPH were evident among the multiracial urban study cohort, as well as varied degrees of response to the medical treatments instituted.
Related Articles
The Impact of Diabetes Type 2 in the Pathogenesis of Benign Prostatic Hyperplasia: A Review
Advances in Urology, 11/10/09
Relevance Score: 85%
Association of Codon 10 Polymorphism of the Transforming Growth Factor Beta 1 Gene with Prostate Cancer and Hyperplasia in an Iranian Population
Urologia Internationalis, 10/16/09
Relevance Score: 84%
Significant Complications following Minimally Invasive Office-Based Treatments for BPH: Experience from a Tertiary Care Center
Current Urology, 11/13/09
Relevance Score: 82%
Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia
Indian Journal of Urology, 10/05/09
Relevance Score: 82%
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Cochrane Reviews, 10/20/09
Relevance Score: 80%
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
European Urology, 12/04/09
Article Search
Sponsor